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Background: Anal cancer requires a multidisciplinary approach to treatment with often complex interventions.
Little is known regarding the associated costs and resource use.
Methods: Patient records were extracted from a national hospital database to estimate the number of patients
treated for anal cancer in England. Identified resource use was linked to published UK cost estimates to quantify
the reimbursement of treatment through the Payment by Results system. A mathematical model was developed
simultaneously to validate findings and to calculate the average 10-year cost of treating a squamous cell anal
carcinoma case from diagnosis. The model utilised data from the Association of Coloproctology of Great Britain
and Ireland's anal cancer position statement.
Results: On average, 1,564 patients were admitted to hospital and 389 attended an outpatient facility per year.
The average annual cost per inpatient and outpatient ranged from £4,562-£5,230 and £1,146-£1,335, respectively.
Based on the model estimates, the inflated cost per case was between £16,470-£16,652. Results were most sensitive
to the mode of admission for primary treatment and the costs of staging/diagnosis (inflated range: £14,309-£23,264).
Conclusions: Despite limitations in the available data, these results indicate that the cost of treating anal cancer is
significant. Further observational work is required in order to verify these findings.
Keywords: Anal cancer, England, Reimbursement, Resource useBackground
Anal cancer is a rare disease, accounting for around 4%
of large bowel malignancies [1]. More than 80% of the
estimated 1,100 cases of anal cancer that are diagnosed
each year in the United Kingdom [2] are squamous cell
carcinomas, the putative aetiological agent for which is
human papillomavirus (HPV) [3], with adenocarcinomas
the next most commonly observed tumour (~10%) [1].
Far less common are anal melanomas, lymphomas and
sarcomas [1]. Some evidence suggests that the incidence
of anal cancer is increasing, with age standardised rates
per 100,000 rising from 0.7 to 1.1 and 0.6 to 1.3 between
1986 and 2003 in English males and females, respectively
[4,5]. Recent epidemiology studies have postulated that
the increase in anal cancer incidence is attributable to* Correspondence: mtempest@pharmerit.com
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unless otherwise stated.changes in sexual behaviour (i.e. a higher number of un-
protected receptive anal sex partners), a likely surrogate
for infection with multiple high-risk HPV strains [6].
Interestingly the incidence of anal cancer has dramatic-
ally increased among HIV-infected men, despite antiviral
therapy (e.g. during and proceeding the HAART era) [7].
One potential explanation for this is that whilst antiviral
therapy may reduce competing mortality risks, it has
no impact on the impact on the natural history of HPV
nor the likelihood or HPV co-infection and, moreover,
increasing life expectancy allows sufficient time for the
accumulation of genetic mutations implicated in the
development of anal cancer. Such data highlights the
need for preventative strategies for anal cancer [7].
Anal cancer is a slow progressing disease and local
disease failures after primary treatment normally go on to
develop metastatic disease. Therefore, the main goal of
curative treatment is achieving adequate local control [8].
Optimal primary treatment involves chemoradiotherapy,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ate the full treatment regime and are at risk of residual
disease as a result [9]. Radical salvage surgery remains
the primary option for those who experience locoregional
relapse [10].
Changes in the treatment approach away from primary
surgical intervention have required a shift to a multi-
disciplinary model of patient management [1]. In England
and Wales, specialist anal cancer multi-disciplinary teams
(MDTs) have been established within and across cancer
networks, with all referrals of suspected cases being dis-
cussed during regular meetings [11]. This is also in keep-
ing with a general strategy aimed at improving outcomes
for rarer cancers, with similar arrangements in place
for penile cancer, which is another HPV-related genital
cancer [12].
In contrast to the well-developed literature on treat-
ment options for anal cancer, very little has been pub-
lished on the costs and resource use associated with
treating the condition. In the last ten years, only two
economic evaluations of treatment for anal cancer have
been carried out in the UK setting [4,13]. Both of these
extrapolated costs from research on other cancers: one
from a study of colorectal cancer [14] and the other
from two studies of cervical cancer costs [15,16].
In order to inform future economic analysis, this study
reports an estimate of both the mean annual costs of
treating anal cancer in England, and also the average
cost of treating a single case of the most common type
of anal cancer, squamous cell carcinoma, in line with
the Association of Coloproctology of Great Britain and
Ireland's anal cancer position statement [1,8,11,17-21].
Methods
The study was split into two phases. Firstly, a retrospect-
ive (non-comparative) case series was performed using
data extracted from the Hospital Episode Statistics
(HES) database. HES includes records of all care funded
by the English National Health Service (NHS), allowing
the economic burden associated with pre-cancerous and
invasive anal cancer lesions in England to be estimated.
Due to the short span of extracted data years, the exclu-
sion of primary care, the inability to distinguish between
initial and recurrent cases, and the lack of information
pertaining to the cancer stage; a separate mathematical
model was developed to simulate the treatment pathway
for an anal cancer case of squamous origin in order to
estimate the average cost of treating a single patient.
HES data collection
For inpatients, finished consultant episodes (FCE) were
extracted based on the presence of any of the following
International Classification of Diseases, 10th (ICD-10)
codes in either the primary, secondary of tertiarydiagnosis field: C210 – malignant neoplasm of anus,
unspecified; C211 – malignant neoplasm of anal canal,
C212 – malignant neoplasm of cloacogenic zone, C218 -
malignant neoplasm overlapping lesion of rectum, anus
and anal cancer, and D013 – carcinoma in situ of anus
and anal canal. Data on outpatient attendances were
confined to records with a primary or secondary diagno-
sis only, reflecting the more disease specific nature of
post-treatment care.
Data were collected for care delivered in the period
from 2006 to 2011. As our HES data request was
submitted prior to the publication of full year results for
2010/2011, the final year was only representative of nine
months of activity in both patient settings.
Approval for use of the HES data was provided by the
information asset owner from the Health and Social
Care Information Centre (HSCIC). The individual HES
records extracted contained no sensitive data and were
pseudonymised preventing the true identification of
patients; analyses pertaining to HES records adhered to
published regulations [22]. Ethical approval was not
required as secondary analysis of HES data can be used
to identify public health issues and for general medical
research under existing protocol; the Health Research
Authority decision tool corroborated this fact stating no
ethical approval was required for this research [23].
Data aggregation and costing
The number of patients undergoing treatment for anal
cancer in each year of the study period was determined
by tracing the unique patient identifiers (HESID)
assigned to each FCE. Mean annual patient numbers
were then calculated. HES data aggregation and the
generation of descriptive statistics was carried out using
SAS Enterprise Guide 4.3.
NHS funded healthcare providers in England are re-
imbursed under the Payment by Results (PbR) scheme
[24]. The currencies for payment under PbR are health-
care resource groups (HRG). Each year, payment tariffs
for each HRG are determined using retrospective ana-
lysis of costing data submitted from previous years. In
order to derive relevant HRGs for care delivered to anal
cancer patients, inpatient FCEs were aggregated into
spells of care (from hospital admission to discharge)
using software publicly available from the NHS [25].
Similarly, for non-admitted patient care (outpatient),
Treatment Function Codes (TFC) and associated HRGs
for consultations or minor procedures were generated.
For all core HRGs and TFCs, costs were calculated using
the National Tariff 2010/11 [26]. Costing analyses were
performed in Excel 2007.
Costs were applied on a per spell basis, accounting for
adjustments such as those for non-elective admissions,
and then aggregated by year. For the final year in the
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nine months of activity, costs and patient numbers were
scaled up by a factor of 1.33, assuming no seasonality in
treatment patterns or propensity to consult.
The annual estimates were then used to calculate mean
annual costs for the duration of the study period, with
mean annual cost per patient calculated by dividing this
by the mean annual number of patients. All analyses were
split by gender, with results for those diagnosed with car-
cinoma in situ of the anus and anal canal also presented
separately to those with invasive disease due to the anti-
cipated differences in treatment intensity for this group.
Under the latest version of HRGs (version 4), some sig-
nificant elements of cost and activity (e.g. chemotherapy,
radiotherapy and rehabilitation) have been ‘unbundled’
from the core HRGs. The frequency of unbundled HRGs
was also captured, with costs associated with the pro-
curement and administration of chemotherapy and
radiotherapy also disaggregated. Unbundled HRGs are
excluded from the National Tariff due to wide variation
in regional practices and costs, with prices negotiated
locally. To derive costs for these unbundled HRGs, the
associated codes were cross-referenced and matched by
description to codes in the Reference Cost Tariffs [27] for
the year of interest. Earlier tariff years were utilised in the
presence of unmatchable codes and inflated accordingly
using the consumer price index (CPI) [28].
Estimating costs over the duration of treatment
To estimate the average cost of treatment for a case of
anal cancer a mathematical model was constructed to
capture the costs of referral through to follow-up, taking
into account the impact of primary treatment on theFigure 1 Markov model structure.duration and intensity of the latter. Due to a lack of data
on outcomes for patients with primary adenocarcinoma,
the model was restricted to anal cancer patients with
squamous cell carcinoma. Data on primary treatment,
disease progression and follow-up for this group were
obtained from the Association of Coloproctology of
Great Britain and Ireland's anal cancer position state-
ment, supplemented by expert opinion where necessary.
First, decision trees were constructed to estimate the
costs of diagnosis, staging, including pre-treatment inter-
ventions such as colostomy surgery, and primary treat-
ment. A Markov model was then developed to simulate
disease progression and follow-up based on the mode of
primary treatment (chemo radiotherapy vs. radiotherapy).
The structure of the Markov portion of the model can
be seen in Figure 1. A one month cycle length was used
and the model was run over a timeframe of ten years
(the extent of high risk follow-up). The initial conditions
assumed that all patients who receive either radiotherapy
or chemo radiotherapy as primary curative treatment are
left disease free. Patients experiencing relapse were as-
sumed to stay in the relapse state for one month only,
representing the period during which salvage interven-
tions occur. Salvage was assumed to be in the form of
abdominoperineal resection (APR).
Monthly probabilities for relapse, death from the dis-
ease free-state and death post relapse (assumed to be the
same for those undergoing salvage or follow-up) were
estimated by calibrating the model to empirical data.
Values for these unknown parameters were jointly se-
lected from within plausible ranges, with simulations
run in batches of 1,000. The best fitting set of values, de-
termined by comparing the model output to longitudinal
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using least squares from each batch of simulations were
then used to determine the ranges from which values were
selected in the next round. We ceased to run simulations
at the point when no improvements were observed in the
overall goodness-of-fit at three significant figures.
All costs applied to treatments and interventions were
taken from the 2010/11 National Tariff, with the 2010/11
Reference Costs used for off tariff payments. Two
scenarios for pricing were examined: 1) with no future
inflation in prices and 2) where future inflation was
assumed to remain constant at 2011/12 levels for the
duration of follow-up [28]. The aim of our approach
was to estimate realised costs as opposed to modelling an
investment decision, therefore discounting was deemed
to be inappropriate. A one-way sensitivity analysis was
also performed for the following key inputs: type of
admission for primary treatment, cost of staging and
primary treatment, monthly costs of palliative care,
intensity of follow-up, proportion of patients undergoing
salvage surgery, proportion of patients presenting with
advanced disease, cost of follow-up interventions and the
proportion of patients receiving chemo radiotherapy.




From 2006-2011, the mean number of patients admitted
to hospital each year in England for invasive anal cancers
was 1,564 (Table 1). Approximately 30% more females
than males were admitted each year on average (mean:
male = 642; female = 922). Over the same period on
average 389 patients attended outpatient facilities each
year for anal cancer (mean: male = 139; female = 250).
The mean start age for anal cancer treatment was 64 and
65 for males and females, respectively (data not shown).
Hospital spells and outpatient attendances
On average, there were 4,674 hospital spells and 3,564









Male 1743 (69) 642 (87) £4,562 (£431)
Female 2931 (290) 922 (81) £5230 (£332)
Anal carcinoma in situ
Male 70 (5) 58 (14) £881 (£336)
Female 133 (32) 110 (32) £1145 (£126)
SD, Standard Deviation.associated with a mean of 3 hospital spells and 10 out-
patient attendances. Female patients had the same num-
ber of hospital spells on average but one less outpatient
attendance. Across genders, the mean length of an
inpatient hospital stay was 4 days.
Eighty-five per cent of hospital spells were elective
admissions and 33% were day case admissions across
both genders. Excess bed days were observed in 10% of
male elective hospital spells and 11% of female elective
hospital spells. For non-elective spells, excess bed days
were observed in 3% for both males and females.
The most frequent HRGs were diagnosis driven anal
disorders of varying severity, representing 47% of male
hospital spells and 51% of female hospital spells. Anal
procedures were the second most observed HRG across
both genders accounting for 8% of hospital spells. Large
intestine disorders and procedures were observed in 12%
and 8% of male and female hospital spells, respectively.
Chemotherapy sessions (procurement and delivery)
were observed in 12% and 11% of male and female hos-
pital spells. Radiotherapy sessions (procurement and deliv-
ery) were observed in 7% of male hospital spells and 9% of
female spells. Across genders, palliative care was associ-
ated with 1% and rehabilitation <1% of hospital spells.
Minor outpatient procedures were observed in 2% of
all attendances. Follow-up consultations were the most
frequent HRG observed in 90% of male and 89% of
female attendances. The most frequent TFC observed
was clinical oncology in 87% and 89% of male and
female attendances, respectively. Chemotherapy sessions
were observed in 1% of male and <1% female atten-
dances, radiotherapy sessions were observed in 29% and
33% of male and female attendances, respectively. Pallia-
tive care and rehabilitation was observed in <1% of all
attendances.
Economic burden
All costs presented considered a direct healthcare per-
spective and are presented in GBP (2011 prices). The
mean annual cost per patient (setting dependent) is








1377 (381) 139 (21) £1335 (£596)
2187 (727) 250 (65) £1146 (£374)
8 (16) 1 (1) £1240 (£1276)
7 (2) 2 (1) £326 (£70)
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females, respectively. Costs per outpatient were calcu-
lated at £1,335 for males and £1,146 for females.
Table 2 provides the total annual cost for anal cancer
defined by gender and per type of care.
For male inpatients, £2,658,450 was attributable to
bundled costs which include all care received in a
hospital setting excluding unbundled HRGs such as
chemotherapy, radiotherapy, rehabilitation, palliative care,
specific diagnostic imaging and high cost drugs. Annual
unbundled costs (excluding chemotherapy and radio-
therapy) were equal to £61,026. Respectively, chemo-
therapy and radiotherapy cost £88,783 and £122,103 per year.
Of the total burden associated with male outpatients,
£120,265 was attributable to bundled costs and £5,096
to unbundled elements of care (excluding chemotherapy
and radiotherapy). Respectively, chemotherapy and
radiotherapy cost £8,332 and £51,214 per year.
Female anal cancer patients were associated with pay-
ments for bundled HRGs totalling £4,351,222 for inpatients
and £191,725 for outpatients; £88,273 for inpatient and
£6,426 outpatient unbundled costs (excluding chemother-
apy and radiotherapy); £132,493 and £2,420 for inpatient
and outpatient chemotherapy, and £251,870 and £86,129
for inpatient and outpatient radiotherapy, respectively.
Across genders and settings, bundled costs accounted
for 89% of the total annual burden. Unbundled costs
accounted for 2%, chemotherapy and radiotherapy ac-
counted for 3% and 6%, respectively. Analysing this
trend, it is clear that the proportion of the cost attri-
butable to chemotherapy and radiotherapy has been
increasing, although this is thought to be predominantly
due to improvements in correct clinical coding as opposed
to changes in the treatment paradigm (Figure 2).
Total costs for duration of treatment
Figure 3 shows the model predictions for cumulative all-










































*Excludes chemotherapy and radiotherapy; SD, Standard Deviation.UKCCR Anal Cancer Trial (ACT 1), for the best fitting
set of parameters which could be achieved through the
calibration process.
The average cost of treating a case of invasive anal
cancer from referral through to either completion of
follow-up or death was estimated to be £16,473 (be-
tween £14,335 and £23,089 based on sensitivity analysis)
when future inflation was taken into account and
£16,281(between £14,143 and £22,884) when it was not.
For those undergoing treatment with curative intent, the
majority of costs were accrued during staging, primary
treatment and the twelve months of follow-up post re-
ferral, with annual costs in the following years ranging
from £338 to £815 (uninflated £308-£807) and £363 to
£1,452 (uninflated £338-£1,437), for those undergoing
chemoradiotherapy and radiotherapy alone, respectively.
Figure 4 shows the results of the one-way sensitivity
analysis used to construct the ranges around the base
case estimates for the inflated scenario (Table 3). The re-
sults were most sensitive to changes in the mode of ad-
mission for primary treatment, reflecting the higher
costs associated with primary treatment that requires
longer patient stays. Changes in the cost of staging and
primary treatment also had a marked impact on the re-
sults, highlighting once again that initial interventions
were the main drivers of total costs. Another implication
of this was that the proportion undergoing salvage had a
limited impact on the results, despite these procedures
being extremely resource intensive.
Discussion
With incidence of anal cancer on the increase, better in-
formation on treatment costs will assist in defining fu-
ture service specifications for commissioning and
delivery of treatment. Although not an incremental ana-
lysis in itself, this study provides the first attempt to esti-
mate the cost of treating anal cancer in England, and





































































Figure 2 Total annual cost distribution per category of care for invasive anal cancer. * Excludes chemotherapy & radiotherapy.
Figure 3 Predicted a) all-cause mortality and b) cumulative relapse compared to data from the UKCCCR anal cancer trial (ACT 1).
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Figure 4 Tornado diagram detailing the one way sensitivity analysis.
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the determination of the costs of current best available
treatment. As with any new data analysis, the research
suffers from some limitations. These mainly stem from
the structure of the HES database and the lack of avail-
able data on disease progression, and associated treat-
ment patterns, for anal cancer.
Firstly it should be acknowledged that despite the
non-comparative case-series study design, the inherent
bias noted with this approach was limited in the present
study. Patient records were extracted from all English
hospitals based on the aforementioned ICD-10 codes
only with no additional inclusion or exclusion criteria
applied. Furthermore, cases were retrieved retrospect-
ively with all information collected routinely in relevant
medical records. Nonetheless, restricting the presence of
an ICD-10 code up to the tertiary and secondary diagno-
ses fields for inpatient and outpatients, respectively may
have introduced some selection bias, for example by ex-
cluding adverse treatment events such as neutropenic
sepsis and radiation proctitis. However, relaxing the this
restriction may have introduced costs completely unre-
lated to anal cancer.
In the HES portion of the analysis, it is evident that
the link between the MDT and clinical coders is ineffi-
cient; most notably in the earlier data years extracted.
Fields such as patient age, sex, admission and discharge
methods, hospital provider codes and codes pertaining
to diagnosis and operational procedures are mandatory
in the grouping process from FCEs to spells of care and
the derivation of the dominant and correct HRGs; the
prevalence of missing fields and thus erroneous codingwas higher within these data years, leading to potential
underestimations within the economic analysis. The
coding errors are recognised under PbR and frameworks
are in place to reduce the percentage of errors in order
to improve the quality of data that underpins PbR. Be-
tween 2007/08 and 2009/10, the audit commission
looked at over £200 million of payments for admitted
patient care, and observed an improvement in the accur-
acy of clinical coding during this period. The coding
error rate dropped from 16% to 11% in three years,
although there remains a wide variation between the
best and worst performing providers. Coding errors
occur at a clinical level and ultimately affect payments.
The Audit Commission estimate that of the £21 billion
spent on the four specialities they audited for three
years, £1 billion (5%) was incorrectly paid [24].
Furthermore, despite HES records containing exhaust-
ive data fields, other key information pertaining to a pa-
tient’s diagnosis would have proved valuable within the
analyses. For example, ICD-10 codes provide a platform
for extracting all records related to anal cancer. How-
ever, it does not provide information pertaining to a
patient’s cancer stage, or if a tumour is primary vs. re-
current. One would naturally assume a higher cost and
more intense resource use as the cancer stage pro-
gresses. This distinction could not be made and there-
fore restricted the performed analysis.
The length of time over which resource use could be
analysed was also constrained by changes to the coding
methodology used in PbR. Data was originally extracted
from 2002/03 to 2010/11 and spanned several versions
of HRG. When aggregating FCEs into spells of care, it
Table 3 Upper and Lower values implemented in the
one-way sensitivity analysis
Scenario/variable Upper value Lower value
Admission type for primary treatment*
Radiotherapy planning £2,869 £729
PICC line insertion £2,068 £751
Procure 5-FU £339 £286
Initial 5-FU cycle delivery £334 £302
Subsequent 5-FU cycle delivery £294 £206
Radiotherapy delivery £261 £111
Cost of staging/primary treatment†
MRI scans £413 £235
CT scans £177 £116
Fine needle aspiration £616 £269
Examination under anaesthetic/biopsy £1,797 £1,117
Radiotherapy planning £1,309 £674
Mytomycin C £48 £40
PICC line insertion £877 £414
Procure 5-FU £360 £187
Initial 5-FU cycle delivery £401 £232
Subsequent 5-FU cycle delivery £343 £210
Radiotherapy delivery £134 £122
Intensity of follow-up
Low-risk of relapse
Follow-up appointments 18 14
MRI scans 2 0
CT scans 2 0
High-risk of relapse
Follow-up appointments 18 14
MRI scans 7 5
CT scans 4 2
Cost of follow-up interventions
MRI scans £413 £235
CT scans £177 £116
*Upper and lower values are for inpatient and outpatient costs, respectively.
†Based on upper and lower quartile of the reference costs for each item.
Keeping et al. BMC Public Health 2014, 14:1123 Page 8 of 10
http://www.biomedcentral.com/1471-2458/14/1123was noted that data prior to 2006 omitted chemotherapy
and radiotherapy unbundled HRGs. The reason for this
was traced to the HRG4 grouping software requirements
on OPCS 4.3 codes for procurement and delivery, which
were not authored and released to the NHS until April
2006. This resulted in severe data gaps associated with
unbundled HRGs from 2002/03 to 2005/06 hence the
decision was taken to restrict the analysis to data from
2006 to 2011.
It should also be noted that outpatient data prior to
2006 was deemed as experimental data due to the imma-
turity of the clinical coding process in this setting. Dataafter this year are accredited as a national statistic. How-
ever, it was increasingly apparent from analysis and ob-
servations of the dataset that this is not of equal quality
to the inpatient dataset. Clinical experts noted that the
observed outpatient numbers were lower than expected:
it is expected a patient admitted to hospital would at-
tend the outpatient facility at least once, which was not
the case here.
High cost drugs are excluded under PbR and no indi-
cation of hospital prescribing data is available within
HES. The exclusion of such costs is acknowledged as an
analytical limitation. Furthermore, costs associated with
unbundled HRGs are not available in the National Tariff
2010/11 due to wide regional variations in resource use
and cost; such prices are locally negotiated. We therefore
used the national average cost from the National Refer-
ence Costs, which provides the foundations for the
National Tariff. Definitions for HRGs can alter yearly and
inaccurately matching codes and definitions could have
potentially led to an underestimation or overestimation.
Nonetheless, the HES analysis does provide the most
complete analysis of the overall burden of anal cancers
to date and is based on a national database currently
used for a range of healthcare analyses for the NHS and
Government. It is from this perspective that HES can be
seen as a useful starting point for costing analyses. These
estimates show that there is a significant burden associ-
ated with treatment of the various tumours and provide
a benchmark against which any future efficiency improv-
ing measures can be judged. Our research also highlights
the limitations of the HES database and difficulty of
calculating the overall burden of specific cancers in
England. Initiatives to improve clinical coding and the
functioning of PbR will be important in aiding future
efforts to quantify the cancer burden.
The mathematical modelling was subject to inherent
data limitations. Firstly, due to a lack of data on stage at
diagnosis and treatment outcomes, we had to assume
that for all patients treated with curative intent, regard-
less of stage, local control was achieved. Although this
assumption is unrealistic, its impact is limited as the
model allows patients to relapse from the first month
post-treatment (assuming a two month gap between
treatment and assessment for response) therefore mir-
roring the treatment which would likely be provided to
those with residual disease. Secondly, data on palliative
care was also limited requiring assumptions about treat-
ment based on expert opinion, with monthly costs ex-
trapolated from studies of resource use patterns for
other tumours. Finally, costs for care delivered during
follow-up outside of the standard pattern of appoint-
ments, for example those related to stoma nurses, could
not be included in the model due to a lack of available
information.
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meant that it was not possible to determine when a par-
ticular patient had entered the post-relapse state, and
consequently it was not possible to accurately apply the
costs of interventions delivered as part of the specified
programme of follow-up for high risk patients. Monthly
follow-up costs post-relapse were therefore based on
an average monthly cost associated with a completed
programme of interventions for those with a high-risk of
relapse. This inability to account for the distribution of
costs for follow-up post salvage surgery, and also the
likely need for palliative interventions, has probably led
to some overall underestimation in the total costs.
It was also assumed that patients receiving salvage sur-
gery would also undergo some cosmetic or reconstruct-
ive surgery. The impact of this assumption was limited
by the small amount that salvage surgery contributed to
total costs overall. It was also not possible to capture the
long term follow-up costs of those undergoing pre-
treatment colostomy, 90% of which are not reversed.
Overall, the assumptions used suggest that the model is
very conservative in estimating overall treatment costs.
Despite these data limitations, the model achieved a
good fit to published data on the natural history of anal
cancer from follow-up data on participants in ACT 1.
The inclusive nature of ACT 1 (those with anal margin
and T1 tumours were not excluded despite their
favourable prognosis) also helps with the generalisability
of the results. Although the model results are not en-
tirely congruent with the per patient costs observed in
HES, this is posited to be the result of annual increases
in new patients pushing per patient costs upwards due
to more resource intensive treatment. The mean annual
costs from the model are also deflated somewhat by the
ten year timeframe used. The inclusion of tumours other
than those of a squamous nature, which are the focus of
the mathematical model, may also have contributed to
the observed differences.
These data are timely given the increasing number of
new interventions aimed at anal cancer, including mono-
clonal antibodies which have been used to treat other
squamous cell carcinomas, such as cetuximab (ERBI-
TUX; ImClone Systems Inc., New York, NY, and Bristol-
Myers Squibb Co, Princeton, NJ), and vaccines against
HPV (e.g. Gardasil, a quadrivalent vaccine developed
and marketed in the UK by Sanofi Pasteur MSD). Suffi-
cient evidence is available to support the causal relation-
ship between HPV-infection and malignant growths of
the anus [30-35]. Low-risk HPV subtypes are more com-
monly associated with low-grade dysplasia, in contrast
to high-risk HPV subtypes (e.g. HPV-16, 18), which are
more frequently identified in carcinoma in situ or inva-
sive carcinoma lesions. Population based epidemiological
studies suggest between 63% and 90% of invasive analcancers are attributable to HPV [30-35].HPV-16 is the
most frequently detected HPV subtype and is prevalent
in an estimated 48.6% to 76.5% of anal cancer cases
[30,31,33,35]. Hitherto, economic evaluations of the
cost-effectiveness of HPV vaccination in the UK have
had to use anal cancer treatment costs extrapolated from
other sources. Our findings can be used as an alternative
and contribute to a more accurate assessment of the
potential value of HPV vaccination.
Conclusions
Despite being a rare condition, anal cancer patients place a
significant burden on NHS resources in England. It is
expected that this should decrease as the impact of the
current HPV vaccination programme for adolescent girls
takes effect. Nonetheless, the reduction may be less than
expected given the group most affected by anal cancer,
men-who-have-sex-with-men (MSM), do not benefit from
the herd protection afforded by the girls programme. Our
estimated treatment costs could now be used to better
estimate the value and cost-effectiveness of vaccination
programmes, particularly those targeted at the male and
MSM populations. This could have important implications
in terms of the expected net health benefit resulting from
preventative healthcare interventions versus existing treat-
ment options and in turn the potential cost offsets to the
NHS. The research also provides a benchmark against
which further changes to the overall structure of service
delivery for anal cancer patients can be judged.
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